Novartis
NEWS
AveXis, a Novartis company, announced interim data from its Phase III STR1VE clinical trial of Zolgensma (onasemnogene abeparvovec-xioi) in spinal muscular atrophy (SMA) Type 1.
Novartis will use a priority review voucher to expedite review of the treatment that could hit blockbuster status within two years of launching.
Alcon CEO says the company is “poised to achieve sustainable growth and create long-term shareholder value as a standalone company.”
Amgen is suing Novartis, alleging a breach of the partnership and seeking to terminate the 2015 contract. Novartis, in response, filed a lawsuit accusing Amgen of inappropriately attempting to end the alliance.
The Novartis subsidiary said it plans to offer jobs to the 150 employees currently working at the Colorado facility and add additional headcount there in the future.
While this type of personalized therapy is revolutionizing cancer treatment and healthcare, it has some formidable limitations.
Novartis will pay $310 million upfront for the Boston-based inflammation company IFM Tre. IFM TRE is very much an early-stage company, with one compound, IFM-2427, in an early Phase I clinical trial, and two preclinical assets.
Novartis will quickly roll Mayzent out to U.S. physicians. The Swiss pharma giant plans to make the drug available within one week of the FDA approval.
Alcon will officially step out from under the Novartis umbrella on April 9 as it will trade on the NYSE and the SIX Swiss Exchange.
JOBS
IN THE PRESS